Supernus Pharmaceuticals Inc (FRA:S49)
€ 34.6 0.6 (1.76%) Market Cap: 1.97 Bil Enterprise Value: 1.62 Bil PE Ratio: 34.78 PB Ratio: 2.04 GF Score: 80/100

Supernus Pharmaceuticals Inc at Cowen Health Care Conference Transcript

Mar 13, 2019 / 01:20PM GMT
Release Date Price: €33.71 (-2.60%)
Ken Cacciatore
Cowen and Company - Analyst

Wanted to kick it off -- thanks for -- Jack and Greg, for making the trip. This is, I'm forgetting how many annual appearances here, but really when you step back and think about where they've been and what Jack and Greg and team have done, where they started and to where they are today, it has really been a fantastic story. So real interested to hear what Jack is going to tell us and I will turn it over to him.

Jack Khattar
Supernus Pharmaceuticals, Inc. - President & CEO

Good morning and thank you, Ken. Before I get started, just remind everyone about the forward-looking statements I will be making through this session and the Q&A session. So please check our SEC filings for the risk factors.

For those of you who may not be familiar with us, very quickly, who is Supernus? It might be a new name, but actually we have been around for more than 25 years. We operated as a division of Shire Pharmaceuticals for several years and develop products for them, products like Adderall XR, Intuniv, Mydayis.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot